FORM PTO-14	49
MCDIFIED	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 207596

APPLICATION NO. 09/720,276

MAY 1 0 2004 P

PATORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Erickson et al.

Erickson et al.
FILING DATE

December 21, 2000

GROUP Unassigned

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS


Examiner's Initials		APPLICATION OR PATENT NUMBER	ISSUE DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
eli.	AA	5,766,842	06/16/1998	Heefner et al.	1	A	MITROFRIATE
1	AB	5,753,660	05/19/1998	Sikorski et al.	1		
	AC	5,728,718	03/17/1998	Randad et al.	1		
	AD	5,723,490	03/03/1998	Tung			<del></del>
	AE	5,705,500	01/06/1998	Getman et al.		<del>\ \ \</del>	
	AF	5,703,076	12/30/1997	Talley et al.	<del></del>	<del>\ \</del>	
	AG	5,502,060	3/26/1996	Thompson	<del></del>	<del> \- </del>	
J	AH	5,475,027	12/12/1995	Talley et al.	<del></del>	<del>                                     </del>	<del></del>

FOREIGN PATENT DOCUMENTS

		DOCUMENT	PUBLICATION	1			TRANS	LATION
		Number	DATE	COUNTRY	CLASS	SUBCLASS	YES	No*
ele	AI	WO 99/67417	12/29/1999	WIPO		1		
	AJ	WO 99/67254	12/29/1999	WIPO				<del> </del>
	AK	WO 99/65870	12/23/1999	WIPO		1-1		<del>                                     </del>
	AL	WO 97/19055	05/29/1997	WIPO		<del>  \                                   </del>		
	AM	WO 96/28463	09/16/1996	WIPO		<del> </del>		
	AN	WO 95/06030	03/02/1995	WIPO	<del></del>	1 1		<u> </u>
	AO	2,276,621	10/05/1994	UK	<del>- \-</del>			
	AP	WO 94/14793	07/07/1994	WIPO	<del>                                     </del>	1 1		
	AQ	WO 94/05639	03/17/1994	WIPO	<del>                                     </del>	1		<del> </del>
1	AR	WO 94/04492	03/03/1994	WIPO	+	<del>                                     </del>		<del>                                     </del>
V	AS	WO 90/09191	08/23/1990	WIPO	<del> </del>			<del> </del>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

al	AT	Bone et al., J. Am. Chem. Soc., 113, 9382 (1991)
	AU	Borman et al., J. Gen. Virology, 77(3), 419-426 (March 1996)
	AV	Erickson et al., Science, 249, 527-533 (1990)
	AW	Ghosh et al., Bioorganic & Medicinal Chemistry Letters, 8, 687-690 (March 1998)
	AX	Ghosh et al., J. Medicinal Chemistry, 36(16), 2300-2310 (August 1993)
	AY	Ghosh et al., J. Medicinal Chemistry, 36(2), 292-294 (January 1993)
	AZ	Ghosh et al., J. Medicinal Chemistry, 37(16), 2506-2508 (August 1994)
	BA	Ghosh et al., J. Medicinal Chemistry, 37, 1177-1188 (April 1994)
	BB	Gulnik et al., Biochemistry, 34(29), 9282-9287 (July 1995)
14	BC	Ho et al., J. Virology, 68(3), 2016-2020 (March 1994)
	BD	Huff, J. Med. Chem., 34(8), 2305-2314 (August 1991)
	BE	Kageyama et al., Antimicrob Agents Chemother., 36, 926-933 (May 1992)
	/ BF	Kaplan et al., PNAS USA, 91, 5597-5601 (1994)



## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 207596

APPLICATION NO. 09/720,276

FORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT Erickson et al.

(Use several sheets if necessary) FILIN

FILING DATE GROUP
December 21, 2000 Unassigned

THAT	BG	Kim et al., J. Medicinal Chemistry, 38(17), 1181-1182 (1995)					
.1	BH	Klabe et al., Biochemistry, 37(24), 8735-8742 (May 1998)					
	BI	Kramer et al., Science, 231, 1580-1584 (1996)					
1	BJ	Lyle et al., J. Med. Chem., 34(3), 1228-1230 (March 1991)					
	BK	Majer et al., 13th American Peptide Symposium, Edmonton, Canada (1993)					
	BL	Martinez-Picado et al. J. Virology, 73(5), 3744-3752 (May 1999)					
1.	ВМ	McQuade et al., Science, 247, 454-456 (1990)					
	BN	Meek et al., Nature, 343(6253), 90-92 (January 1990)					
	ВО	Meek, J. Enzyme Inhibition, 6(1), 65-98 (January 1992)					
	BP	Moore et al., Perspect. Drug Dis. Design, 1, 85-108 (1993)					
	BQ	Norbeck et al., Ann. Reports Med. Chem., 26, 141-150 (1991)					
	BR	Otto et al., PNAS USA, 90, 7543-7547 (1993)					
·	BS	Plattner et al., Drug Discovery Technologies, Clark et al., eds., Ellish Horwood, Chichester, England, 92-126 (1990)					
	BT	Rich et al., J. Med. Chem., 33(5), 1285-1288 (May 1990)					
	BU	Roberts et al., Science, 248, 358-361 (1990)					
	BV	Tomasselli et al., Int. J. Chem. Biotechnology, 6, 6-27 (1991)					
	BW	Vacca et al., J. Med. Chem., 34(3), 1225-1228 (March 1991)					
V	BX	Vazquez et al., J. Medicinal Chemistry, 38(4), 581-584 (February 1995)					
EXAMINER (	22 L	DATE CONSIDERED 2/2/1					

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(b).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(b).

Please type a plus sign (+) inside this box ->	干
--	---

				Complete if Known				
Substitute for fo	om 1449A/B/PTO			Application Number	09/720,276	_		
INIE	DRMATION I	nie (	N OCHDE	Filing Date	March 7, 2001	_		
				First Named Inventor	Erickson	_		
STATEMENT BY APPLICANT				Group Art Unit	1648	_		
	(Use as many sheet	s as nec	cessary)	Examiner Name	Le, E.	_		
Sheet 1 of 1			1	Attorney Docket Number	207596	_		

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
Q 00	BY	∕ EP	0 337 714	A2	Merck & Co.	Oct. 18, 1989		
1	BZ	/ EP	0 434 365	A2	Merck & Co.	June 26, 1991		
	CA	EP	0 528 661	A2	Merck & Co.	Feb. 24, 1993		
	СВ	ÉP	0 539 192	B1	Merck & Co.	Apr. 28, 1993	·	<u> </u>
	CC.	ÉP.	0 534 511	A1	Merck & Co.	Mar. 31, 1993		Ì
	CD	/ EP	0 550 924	A1	Merck & Co.	July 14, 1993		
	CE	/ Wo	90/09191	A1	Schramm et al.	Aug. 23, 1990		+
$\overline{V}$	CF	7WO	00/48466	A2	Okla. Med. Res. Found.	Aug. 24, 2000		

	,	OTHER - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T	1-4:
Examiner Initials	Doc. No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	lation No**
ile	C G/ Chakraborty et al., Tetrahedron Letters, 41, 10121-10125 (2000)			
1	CH/	Ghosh et al., Drug Design and Discovery, 10, 77-88 (1993)		
	CI/	Ghosh et al., J. Med. Chem., 36, 924-927 (1993)		
	Clv	Ghosh et al., 207 <sup>th</sup> American Chem. Soc. Nat'l Meeting, Medi 37 (March 13-17, 1994)		
	CK,	Ghosh et al., 210th American Chem. Soc. Nat'l Meeting, Medi 27 (Aug. 20-24, 1995)		
	CL/	Ghosh et al., Bioorganic & Med. Chem. Lett., 5 (1), 83-88 (1995)		
	CM/	Ghosh et al., Tetrahedron Letters, 36 (4), 505-508 (1995)		
	CN/	Ghosh et al., J. Med. Chem., 39, 3278-3290 (1996)		
	CO/	Ghosh et al., 216 <sup>th</sup> American Chem. Soc. Nat'l Meeting, Medi 229 (1998)		
	C P / Ghosh et al., Bioorganic & Med. Chem. Lett., 8, 979-982 (1998)			
	C Q / Ghosh et al., Tetrahedron Letters, 39, 4651-4654 (1998)			
	CR,	Ghosh et al., 39 <sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif,., Session 89F, paper 928, (Sep. 26-29, 1999)		
	CS <sup>2</sup>	Ghosh et al.; Antiviral Research, 51, p. 26, Abstract 035 (2001)		
	CT/	Ghosh et al., Il Farmaco, 56, 29-32 (2001)		
	CU	Ghosh et al., J. Med. Chem., 44, 2865-2868 (2001)		
	CV-	Holloway et al., J. Med. Chem., 38, 305-317 (1995)		
	CW	Hong et al., Science, 290 (5489), 150-153, (Oct. 6, 2000)		
	CX	Huff et al., Journal of Cellular Biochemistry., p. 130, S 037 (Feb. 26-Apr. 17, 1994)		
	CY	Koh et al., Antimicrob. Agents Chemother., 47, 3123-3129 (2003)		
	CZ-	Ray et al., <i>Apoptosis</i> , <i>5</i> , 509-514 (2000)		
	DA/	Turner et al., Biochemistry, 40 (34), 10001-10006 (Aug. 28, 2001)		
	DB a	Upadhyaya et al., Arch. Virol., 140, 1945-1956 (1995)		
		Walia et al., Infection and Immunity, 67, 5215-5222 (Oct. 1999)		
V		Yoshimura et al., J. Virol., 1349-1358 (Feb. 2002)	74	

Examiner Signature	Enuly de	Date Considered	7/08/0-	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).